drug · small molecule
TAZAROTENE
Marketedupdated 3mo agoby $GRI GRI Bio, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 3 investigational indications.
indications
investigational
Pulmonary Fibrosis
targets
Retinoic acid receptor
all catalysts(1)
Trials studying TAZAROTENE
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 24, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 11, 2038method-of-use (U-2368)US 11311482
- May 11, 2038formulationUS 12128137
- Jun 6, 2036formulationUS 11679116
- Feb 24, 2030formulationUS 105688593.5y
- Feb 24, 2030formulationUS 106880713.5y
- Feb 24, 2030formulationUS 88087163.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that